{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:11:42Z","timestamp":1790611902957,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0525700"],"award-info":[{"award-number":["2024ZD0525700"]}]},{"name":"The National Key Research and Development Program of China","award":["2023YFC2507000"],"award-info":[{"award-number":["2023YFC2507000"]}]},{"name":"Innovation Fund for Qutstanding Doctoral Candidates of Peking University Health Science Center","award":["BMU2024BSS001"],"award-info":[{"award-number":["BMU2024BSS001"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82471866, 82271877, 82472912"],"award-info":[{"award-number":["82471866, 82271877, 82472912"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural science foundation of Beijing, China","award":["7242150"],"award-info":[{"award-number":["7242150"]}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z221100007422097"],"award-info":[{"award-number":["Z221100007422097"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Capital's Funds for Health Improvement and Research of China","award":["2022-4-4087"],"award-info":[{"award-number":["2022-4-4087"]}]},{"name":"Peking University People's Hospital Scientific Research Development Funds","award":["RDGS2022-02, RDX2024-01"],"award-info":[{"award-number":["RDGS2022-02, RDX2024-01"]}]},{"DOI":"10.13039\/501100002858","name":"the China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2025M781883"],"award-info":[{"award-number":["2025M781883"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16326-2","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:05:11Z","timestamp":1781327111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of bladder cancer patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Poning","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinbo","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaye","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"issue":"3","key":"16326_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"19","key":"16326_CR2","first-page":"1980","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. JAMA. 2020;324(19):1980\u201391.","journal-title":"Bladder Cancer: Rev Jama"},{"issue":"4","key":"16326_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s11427-020-1768-y","volume":"64","author":"Z Wu","year":"2021","unstructured":"Wu Z, Liu J, Dai R, Wu S. Current status and future perspectives of immunotherapy in bladder cancer treatment. Sci China Life Sci. 2021;64(4):512\u201333.","journal-title":"Sci China Life Sci"},{"issue":"11","key":"16326_CR4","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25(11):1706\u201314.","journal-title":"Nat Med"},{"key":"16326_CR5","doi-asserted-by":"publisher","unstructured":"Jiang S, Song Y, Peng Y, Yan R, Niu Y, Chen B et al. Patient-derived organoid-immune co-cultures integrated with multi-omics reveal immunotherapy resistance mechanisms in urothelial carcinoma. iMeta. 2026:e70130. https:\/\/doi.org\/10.1002\/imt2.70130.","DOI":"10.1002\/imt2.70130"},{"key":"16326_CR6","first-page":"2","volume":"7","author":"P Spiliopoulou","year":"2024","unstructured":"Spiliopoulou P, Kaur P, Hammett T, Di Conza G, Lahn M, Targeting T. regulatory (T(reg)) cells in immunotherapy-resistant cancers. Cancer drug Resist. 2024;7:2.","journal-title":"Cancer drug Resist (Alhambra Calif)"},{"issue":"3","key":"16326_CR7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.56434\/j.arch.esp.urol.20267903.48","volume":"79","author":"S Navarro-Jim\u00e9nez","year":"2026","unstructured":"Navarro-Jim\u00e9nez S, Carri\u00f3n-L\u00f3pez P, Lorenzo-S\u00e1nchez MV, T\u00e1rraga-Honrubia MA, D\u00edaz-de-Mera-S\u00e1nchez-Migall\u00f3n I, Gim\u00e9nez-Bachs JM, et al. Association of Inflammatory and Nutritional Biomarkers with Pathological Response in Patients with Muscle-invasive Bladder Carcinoma Treated with Neoadjuvant Chemotherapy. Arch Esp Urol. 2026;79(3):404\u201314.","journal-title":"Arch Esp Urol"},{"issue":"7867","key":"16326_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432\u20137.","journal-title":"Nature"},{"issue":"27","key":"16326_CR9","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","volume":"26","author":"MC Dieu-Nosjean","year":"2008","unstructured":"Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410\u20137.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"17","key":"16326_CR10","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1158\/0008-5472.CAN-11-0431","volume":"71","author":"L Martinet","year":"2011","unstructured":"Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011;71(17):5678\u201387.","journal-title":"Cancer Res"},{"issue":"8","key":"16326_CR11","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-13-2590","volume":"20","author":"G Di Caro","year":"2014","unstructured":"Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res. 2014;20(8):2147\u201358.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"11","key":"16326_CR12","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/bjc.2015.145","volume":"112","author":"N Hiraoka","year":"2015","unstructured":"Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer. 2015;112(11):1782\u201390.","journal-title":"Br J Cancer"},{"issue":"9","key":"16326_CR13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00262-007-0286-3","volume":"56","author":"A Lad\u00e1nyi","year":"2007","unstructured":"Lad\u00e1nyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunotherapy. 2007;56(9):1459\u201369.","journal-title":"Cancer Immunol immunotherapy: CII"},{"issue":"6","key":"16326_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307\u201325.","journal-title":"Nat Rev Cancer"},{"key":"16326_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3389\/fimmu.2016.00491","volume":"7","author":"NH Ruddle","year":"2016","unstructured":"Ruddle NH. High Endothelial Venules and Lymphatic Vessels in Tertiary Lymphoid Organs: Characteristics, Functions, and Regulation. Front Immunol. 2016;7:491.","journal-title":"Front Immunol"},{"issue":"6","key":"16326_CR16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1158\/2326-6066.CIR-18-0758","volume":"7","author":"C Pfannstiel","year":"2019","unstructured":"Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, et al. The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunol Res. 2019;7(6):923\u201338.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"16326_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3233\/BLC-170120","volume":"3","author":"M Koti","year":"2017","unstructured":"Koti M, Xu AS, Ren KYM, Visram K, Ren R, Berman DM, et al. Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer. Bladder Cancer. 2017;3(4):259\u201367.","journal-title":"Bladder cancer (Amsterdam Netherlands)"},{"issue":"7","key":"16326_CR18","first-page":"e2410998","volume":"12","author":"J Lin","year":"2025","unstructured":"Lin J, Jiang S, Chen B, Du Y, Qin C, Song Y, et al. Tertiary Lymphoid Structures are Linked to Enhanced Antitumor Immunity and Better Prognosis in Muscle-Invasive Bladder Cancer. Adv Sci. 2025;12(7):e2410998.","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"16326_CR19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178\u201389.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"16326_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, C\u00f4t\u00e9 P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280\u20136.","journal-title":"Ann Intern Med"},{"issue":"7109","key":"16326_CR21","first-page":"629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"4","key":"16326_CR22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101.","journal-title":"Biometrics"},{"key":"16326_CR23","doi-asserted-by":"crossref","unstructured":"Chen C, An M, Zheng H, Pang M, Li Y, Diao X et al. B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. Cancer Cell. 2026;44(3):551\u201366. e17.","DOI":"10.1016\/j.ccell.2025.12.011"},{"issue":"10","key":"16326_CR24","doi-asserted-by":"publisher","first-page":"e70978","DOI":"10.1002\/cam4.70978","volume":"14","author":"X Teng","year":"2025","unstructured":"Teng X, Chen Z, Bai Y, Cao H, Zhang J, Xu L, et al. Tertiary Lymphoid Structures as Independent Predictors of Favorable Prognosis in Muscle-Invasive Bladder Cancer. Cancer Med. 2025;14(10):e70978.","journal-title":"Cancer Med"},{"issue":"3","key":"16326_CR25","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.ijrobp.2025.09.056","volume":"124","author":"N Hassan","year":"2026","unstructured":"Hassan N, Michaud E, Mansure JJ, Farag M, Kool R, Alessa M, et al. The Clinical Relevance of Tertiary Lymphoid Structures in Assessing Treatment Response in Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2026;124(3):726\u201332.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"16326_CR26","doi-asserted-by":"publisher","first-page":"e45013","DOI":"10.1016\/j.urolonc.2024.06.010","volume":"42","author":"F Yilmaz","year":"2024","unstructured":"Yilmaz F, Sagir S. Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: Should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method? Urol Oncol. 2024;42(12):e45013\u201322.","journal-title":"Urol Oncol"},{"issue":"2","key":"16326_CR27","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1093\/oncolo\/oyad283","volume":"29","author":"G Ma","year":"2024","unstructured":"Ma G, Jia H, Zhang G, Liang Y, Dong X, Fu G, et al. Presence, Subtypes, and Prognostic Significance of Tertiary Lymphoid Structures in Urothelial Carcinoma of the Bladder. Oncologist. 2024;29(2):e248\u201358.","journal-title":"Oncologist"},{"key":"16326_CR28","doi-asserted-by":"crossref","unstructured":"Masuda T, Tanaka N, Takamatsu K, Hakozaki K, Takahashi R, Anno T et al. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. J Immunother Cancer. 2022;10(3):e003883.","DOI":"10.1136\/jitc-2021-003883"},{"issue":"1","key":"16326_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12967-025-06358-w","volume":"23","author":"W Wahafu","year":"2025","unstructured":"Wahafu W, Zhou Q, Yang X, Yang Y, Zhao Y, Wang Z, et al. Spatial relationships and interactions of immune cell niches are linked to the pathologic response of muscle-invasive bladder cancer to neoadjuvant therapy. J Transl Med. 2025;23(1):375.","journal-title":"J translational Med"},{"issue":"1","key":"16326_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41591-024-03324-9","volume":"31","author":"R Li","year":"2025","unstructured":"Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, et al. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025;31(1):176\u201388.","journal-title":"Nat Med"},{"issue":"7","key":"16326_CR31","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s41416-024-02598-7","volume":"130","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zhang R, Jin D, Zhang T, Shahatiaili A, Zang J, et al. Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer. Br J Cancer. 2024;130(7):1221\u201331.","journal-title":"Br J Cancer"},{"issue":"12","key":"16326_CR32","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N van Dijk","year":"2020","unstructured":"van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839\u201344.","journal-title":"Nat Med"},{"issue":"6","key":"16326_CR33","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.euo.2020.06.009","volume":"3","author":"M Rouanne","year":"2020","unstructured":"Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, et al. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol. 2020;3(6):728\u201338.","journal-title":"Eur Urol Oncol"},{"key":"16326_CR34","doi-asserted-by":"crossref","unstructured":"Gupta S, Sonpavde G, Weight CJ, McGregor BA, Gupta S, Maughan BL et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol. 2020;38(6_suppl):439\u2013439.","DOI":"10.1200\/JCO.2020.38.6_suppl.439"},{"key":"16326_CR35","doi-asserted-by":"publisher","first-page":"107230","DOI":"10.1016\/j.phrs.2024.107230","volume":"205","author":"Y Song","year":"2024","unstructured":"Song Y, Jiang S, Peng Y, Qin C, Du Y, Xu T. Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma. Pharmacol Res. 2024;205:107230.","journal-title":"Pharmacol Res"},{"issue":"2","key":"16326_CR36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1158\/0008-5472.CAN-25-0024","volume":"86","author":"J Wu","year":"2026","unstructured":"Wu J, Cheng B, Song Y, Cheng J, Gao H, Luo X, et al. Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer. Cancer Res. 2026;86(2):519\u201339.","journal-title":"Cancer Res"},{"issue":"4","key":"16326_CR37","first-page":"306","volume":"1","author":"H Zhang","year":"2023","unstructured":"Zhang H, Chen J, Zhang Q, Yu L, Li X, Wu S. Oncogenic viral antigens for engineered T cell immunotherapy. Challenges opportunities. Med Adv. 2023;1(4):306\u201317.","journal-title":"Challenges opportunities"},{"issue":"1","key":"16326_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40291-023-00679-6","volume":"28","author":"N Conci","year":"2024","unstructured":"Conci N, Tassinari E, Tateo V, Rosellini M, Marchetti A, Ricci C, et al. How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? Mol Diagn Ther. 2024;28(1):37\u201351.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"16326_CR39","doi-asserted-by":"publisher","first-page":"2440165","DOI":"10.1080\/21645515.2024.2440165","volume":"21","author":"E Tassinari","year":"2025","unstructured":"Tassinari E, Danielli L, Marchetti A, Rosellini M, Ricci C, Piazza P, et al. State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes. Hum Vaccin Immunother. 2025;21(1):2440165.","journal-title":"Hum vaccines immunotherapeutics"},{"key":"16326_CR40","doi-asserted-by":"crossref","unstructured":"Groeneveld CS, Fontugne J, Cabel L, Bernard-Pierrot I, Radvanyi F, Allory Y et al. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Eur J Cancer (Oxford, England: 1990). 2021;148:181\u20139.","DOI":"10.1016\/j.ejca.2021.01.036"},{"issue":"10","key":"16326_CR41","doi-asserted-by":"publisher","first-page":"e1074","DOI":"10.1002\/ctm2.1074","volume":"12","author":"Y Ling","year":"2022","unstructured":"Ling Y, Zhong J, Weng Z, Lin G, Liu C, Pan C, et al. The prognostic value and molecular properties of tertiary lymphoid structures in oesophageal squamous cell carcinoma. Clin Transl Med. 2022;12(10):e1074.","journal-title":"Clin translational Med"},{"issue":"1","key":"16326_CR42","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1038\/s41467-021-23355-x","volume":"12","author":"AT Ruffin","year":"2021","unstructured":"Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar S, Kunning SR, et al. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun. 2021;12(1):3349.","journal-title":"Nat Commun"},{"issue":"7","key":"16326_CR43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Saut\u00e8s-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19(7):441\u201357.","journal-title":"Nat reviews Clin Oncol"},{"issue":"3","key":"16326_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","volume":"74","author":"J Goc","year":"2014","unstructured":"Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8\u2009+\u2009T cells. Cancer Res. 2014;74(3):705\u201315.","journal-title":"Cancer Res"},{"issue":"1","key":"16326_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12935-025-03635-y","volume":"25","author":"X Fan","year":"2025","unstructured":"Fan X, Feng D, Wei D, Li A, Wei F, Deng S, et al. Characterizing tertiary lymphoid structures associated single-cell atlas in breast cancer patients. Cancer Cell Int. 2025;25(1):12.","journal-title":"Cancer Cell Int"},{"key":"16326_CR46","doi-asserted-by":"crossref","unstructured":"Narvaez D, Nadal J, Nervo A, Costanzo MV, Paletta C, Petracci FE et al. The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review. Cancers (Basel). 2024;16(2):396.","DOI":"10.3390\/cancers16020396"},{"issue":"7791","key":"16326_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561\u20135.","journal-title":"Nature"},{"issue":"6576","key":"16326_CR48","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375(6576):eabf9419.","journal-title":"Sci (New York NY)"},{"issue":"12","key":"16326_CR49","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/ni.3290","volume":"16","author":"S Finkin","year":"2015","unstructured":"Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16(12):1235\u201344.","journal-title":"Nat Immunol"},{"issue":"1","key":"16326_CR50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","volume":"70","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Petitprez F, Becht E, Laurent A, Hirsch TZ, Rousseau B, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol. 2019;70(1):58\u201365.","journal-title":"J Hepatol"},{"key":"16326_CR51","doi-asserted-by":"crossref","unstructured":"Sun X, Liu W, Sun L, Mo H, Feng Y, Wu X et al. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2022;10(11):e005531.","DOI":"10.1136\/jitc-2022-005531"},{"issue":"11","key":"16326_CR52","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41590-024-01992-w","volume":"25","author":"DH Shu","year":"2024","unstructured":"Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, et al. Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma. Nat Immunol. 2024;25(11):2110\u201323.","journal-title":"Nat Immunol"},{"issue":"7","key":"16326_CR53","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24(7):994\u20131004.","journal-title":"Nat Med"},{"issue":"5","key":"16326_CR54","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","volume":"78","author":"K Sili\u0146a","year":"2018","unstructured":"Sili\u0146a K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, et al. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. Cancer Res. 2018;78(5):1308\u201320.","journal-title":"Cancer Res"},{"key":"16326_CR55","doi-asserted-by":"crossref","unstructured":"Paner GP, Kamat A, Netto GJ, Samaratunga H, Varma M, Bubendorf L et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol. 2024;48(1):e11\u2013e23.","DOI":"10.1097\/PAS.0000000000002077"},{"key":"16326_CR56","doi-asserted-by":"crossref","unstructured":"van der Kwast TH, Bubendorf L, Cheng L. International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer: Main Conclusions and Recommendations. Eur Urol. 2024;85(5):411\u20133.","DOI":"10.1016\/j.eururo.2024.02.009"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16326-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16326-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16326-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:08:11Z","timestamp":1787105291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16326-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16326"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16326-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"999"}}